ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks Education
Visit Zacks' Education section for investing guides and other free resources to make you a better investor.

Quote:

Search for Ticker

Free Membership

Search:

ENZN: Enzon Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ENZON PHARMACEUTICALS INC (NASD)
ENZN	10.37	N/A	(N/A%)	Vol. 0	N/A ET

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets ABELCET, ONCASPAR, ADAGEN, and DEPOCYT in the United States. In addition, Enzon also receives royalties on sales of PEG-INTRON, marketed by Schering-Plough Corporation, and MACUGEN, marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon also utilizes contract manufacturing opportunities to broaden its revenue base and enhance its organizational productivity. Enzon complements its internal research and development efforts with strategic initiatives.

General Information

ENZON PHARMA

685 Route 202/206 Bridgewater, NJ 08807 Phone: 908 541-8600 Fax: 908 575-9457 Web: www.enzon.com Email: investor@enzon.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/18/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	10.37
52 Week High	10.80
52 Week Low	4.37
Beta	1.25
20 Day Moving Average	716,153.88
Target Price Consensus	11.75

% Price Change
4 Week	14.03
12 Week	43.53
YTD	77.01

% Price Change Relative to S&P 500
4 Week	12.80
12 Week	35.32
YTD	46.50

Share Information
Shares Outstanding (millions)	45.40
Market Capitalization (millions)	468.49
Short Ratio	11.33
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.06
Current Year EPS Consensus Estimate	-0.12
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	02/18/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	3.00
30 Days Ago	3.00
60 Days Ago	3.00
90 Days Ago	3.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	100.00%
vs. Previous Quarter	100.00%

Sales Growth
vs. Previous Year	-8.59%
vs. Previous Quarter:	-5.49%

Price Ratios
Price/Book	9.08
Price/Cash Flow	32.44
Price / Sales	2.48

ROE
09/30/09	-7.82
06/30/09	-13.00
03/31/09	-3.25

ROA
09/30/09	-1.10
06/30/09	-1.71
03/31/09	-0.40

Current Ratio
09/30/09	-
06/30/09	5.93
03/31/09	6.46

Quick Ratio
09/30/09	-
06/30/09	5.27
03/31/09	5.86

Operating Margin
09/30/09	-1.96
06/30/09	-3.03
03/31/09	-0.71

Net Margin
09/30/09	-
06/30/09	-0.66
03/31/09	1.05

Pre-Tax Margin
09/30/09	-
06/30/09	-0.66
03/31/09	1.05

Book Value
09/30/09	-
06/30/09	1.14
03/31/09	1.12

Inventory Turnover
09/30/09	-
06/30/09	3.09
03/31/09	3.24

Debt-to-Equity
09/30/09	-
06/30/09	5.01
03/31/09	4.97

Debt to Capital
09/30/09	-
06/30/09	83.37
03/31/09	83.24


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research